- Home
- PETZ vs NEUP Comparison
PETZ vs NEUP Comparison
Compare PETZ & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- NEUP
- Stock Information
- Founded
- PETZ 2002
- NEUP 1996
- Country
- PETZ China
- NEUP United States
- Employees
- PETZ N/A
- NEUP N/A
- Industry
- PETZ Steel/Iron Ore
- NEUP
- Sector
- PETZ Industrials
- NEUP
- Exchange
- PETZ Nasdaq
- NEUP Nasdaq
- Market Cap
- PETZ 10.9M
- NEUP 10.3M
- IPO Year
- PETZ 2017
- NEUP N/A
- Fundamental
- Price
- PETZ $1.03
- NEUP $4.93
- Analyst Decision
- PETZ
- NEUP Strong Buy
- Analyst Count
- PETZ 0
- NEUP 2
- Target Price
- PETZ N/A
- NEUP $28.00
- AVG Volume (30 Days)
- PETZ 8.1K
- NEUP 4.8M
- Earning Date
- PETZ 12-16-2025
- NEUP 11-21-2025
- Dividend Yield
- PETZ N/A
- NEUP N/A
- EPS Growth
- PETZ N/A
- NEUP N/A
- EPS
- PETZ 0.26
- NEUP N/A
- Revenue
- PETZ $563,726.00
- NEUP $15,649,448.00
- Revenue This Year
- PETZ N/A
- NEUP N/A
- Revenue Next Year
- PETZ N/A
- NEUP N/A
- P/E Ratio
- PETZ $5.04
- NEUP N/A
- Revenue Growth
- PETZ 74664.72
- NEUP N/A
- 52 Week Low
- PETZ $0.65
- NEUP $2.90
- 52 Week High
- PETZ $1.68
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- PETZ 42.95
- NEUP 37.16
- Support Level
- PETZ $1.03
- NEUP $4.09
- Resistance Level
- PETZ $1.07
- NEUP $5.18
- Average True Range (ATR)
- PETZ 0.05
- NEUP 0.64
- MACD
- PETZ -0.00
- NEUP 0.11
- Stochastic Oscillator
- PETZ 0.00
- NEUP 21.51
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About NEUP Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.